Generic Name: apalutamide

Pronunciation: er-LEE-da

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Hormone Therapy Medications

Company: Janssen Therapeutics

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Erleada is an androgen receptor inhibitor approved for nonmetastatic prostate cancer that progresses despite low testosterone levels (known as castration resistant).

General Info

Testosterone and other male hormones (androgens) stimulate prostate cancer growth. To do so, they must bind to androgen receptors in prostate cells. Erleada blocks signals from androgen receptors, preventing them from triggering cancer proliferation. It should be combined with drugs such as GnRH agonists that reduce testosterone production, known as androgen deprivation therapy (ADT).

In the SPARTAN trial, Erleada plus androgen deprivation therapy delayed prostate cancer metastasis and improved progression-free survival compared to ADT alone.


Dosing Info:

Erleada is taken as pill. The usual dose is four tablets taken together once daily with or without food.

Side Effects

Common side effects include fatigue, skin rash, hot flashes, diarrhea, nausea, decreased appetite, weight loss, joint pain, high blood pressure and swelling. Seizures are a less common but potentially serious side effect. Erleada has been associated with an increased risk of falling and bone fractures.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: September 19, 2018